MAPS Act
Summary
The MAPS Act (S.1784) is a bipartisan bill requiring the FDA to maintain and update an essential medicines list and assess supply chain vulnerabilities. It is currently at the hearing stage in the Senate HELP Committee. No explicit funding is authorized; the bill imposes reporting and risk-assessment mandates. For healthcare companies, the direct near-term revenue impact is negligible, but the bill signals a long-term government focus on reducing drug shortages, which may indirectly favor companies with robust supply chain management.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill is in early stage - hearings completed, no mark-up yet
- 2.No direct funding or tax incentives - reporting mandate only
- 3.Ticker impact is negligible; no pure-play public company from provided list is clearly benefited
Market Implications
Given the absence of direct revenue mechanisms, the MAPS Act does not change the financial outlook for large-cap healthcare companies. The bill does not threaten pricing, patent protection, or prescribing patterns. The market should treat this as a procedural development with no actionable trade signal. No real market data was provided to reference price movements.
Full Analysis
-
What happened - The Mapping America's Pharmaceutical Supply Act (MAPS Act) was introduced in May 2025 by Sen. Peters with bipartisan cosponsors. Hearings were held in the Senate HELP Committee in March2026. The bill has not yet been marked up or reported out. It is a relatively early-stage authorization bill with no companion House bill passed yet.
-
Money trail - The bill does not include any direct appropriation. It authorizes the FDA to update the essential medicines list and conduct risk assessments. Any funding would require a separate appropriations bill. The Congressional Budget Office (CBO) cost estimate has not been released, but the mandate is likely to be low-cost (<$50M annually) for FDA operations.
-
Convergence - No other related signals or procurement actions were provided. The bill stands alone as a healthcare supply-chain security measure. It aligns with broader government efforts to reduce pharmaceutical dependence on foreign sources (e.g., Executive Order 13944) but is not part of a current legislative wave.
-
Winners and losers - Direct public companies from the provided set are not clearly beneficiaries. The bill imposes compliance burdens on FDA and indirectly on drug manufacturers. Large pharmaceutical companies (e.g., $JNJ, $PFE) already have mature supply chain operations; the main effect is incremental reporting cost. No company is positioned for revenue increase from this bill. The main structural long-term winner could be companies focused on supply chain analytics or generic essential drug manufacturing (private or publicly traded but not in list). This bill is a procedural step with minimal near-term market impact.
-
Timeline - The bill is in the HELP Committee. Next steps: mark-up, committee vote, then floor consideration. Given the bipartisen support, passage is possible in 2026 or 2027. But the 119th Congress timeline is uncertain.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
HUMAN SERVICES, NEW JERSEY DEPARTMENT OF: $16.9B Department of Health and Human Services Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
GOVERNOR'S AUTHORIZED REPRESENTATIVE: $1.8B Department of Homeland Security Grant
DEPARTMENT OF SOCIAL SERVICES MISSO: $15.1B Department of Health and Human Services Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →